Vignesh Rajah Biography and Net Worth

Vignesh Rajah, MBBS, DCH, MRCP(UK), MBA, serves as SVP, Chief Medical Officer. Dr Rajah qualified as physician in University of London, and has 10 years’ experience in hospital practice, specializing in Internal Medicine and Paediatric Critical Care in the UK. He brings extensive experience in Medical Affairs since joining the industry in 2001, with roles of increasing seniority in global pharma companies including Sanofi, Wyeth and most recently GSK, covering multiple therapeutic areas such as Oncology, Vaccines, Immunology and Respiratory. In his most recent role in GSK, (2015-2020) he was VP, Europe Area Medical Head managing a large medical organization, accountable for medical affair activities in pre-launch and post-launch phase, life-cycle management of medicines, safety & pharmacovigilance, medical governance, and building industry-leading medical capabilities.

What is Vignesh Rajah's net worth?: The estimated net worth of Vignesh Rajah is at least $280,600.92 as of March 5th, 2024. Dr. Rajah owns 33,889 shares of Y-mAbs Therapeutics stock worth more than $280,601 as of December 22nd. This net worth estimate does not reflect any other investments that Dr. Rajah may own. Additionally, Dr. Rajah receives a salary of $406,270.00 as CMO at Y-mAbs Therapeutics. Learn More about Vignesh Rajah's net worth.
How old is Vignesh Rajah?: Dr. Rajah is currently 59 years old. There are 7 older executives and no younger executives at Y-mAbs Therapeutics. The oldest executive at Y-mAbs Therapeutics is Dr. Torben Lund-Hansen M.Sc., Ph.D., Senior VP & CTO, who is 73 years old. Learn More on Vignesh Rajah's age.
What is Vignesh Rajah's salary?: As the CMO of Y-mAbs Therapeutics, Inc., Dr. Rajah earns $406,270.00 per year. There are 3 executives that earn more than Dr. Rajah. The highest earning executive at Y-mAbs Therapeutics is Mr. Thomas Gad, Founder, Chief Business Officer & Vice Chairman, who commands a salary of $1,050,000.00 per year. Learn More on Vignesh Rajah's salary.
How do I contact Vignesh Rajah?: The corporate mailing address for Dr. Rajah and other Y-mAbs Therapeutics executives is 230 Park Avenue Suite 3350, NEW YORK NY, 10169. Y-mAbs Therapeutics can also be reached via phone at (646) 885-8505 and via email at [email protected]. Learn More on Vignesh Rajah's contact information.
Has Vignesh Rajah been buying or selling shares of Y-mAbs Therapeutics?: Vignesh Rajah has not been actively trading shares of Y-mAbs Therapeutics over the course of the past ninety days. Most recently, Vignesh Rajah sold 1,711 shares of the business's stock in a transaction on Tuesday, March 5th. The shares were sold at an average price of $16.53, for a transaction totalling $28,282.83. Following the completion of the sale, the senior vice president now directly owns 33,889 shares of the company's stock, valued at $560,185.17. Learn More on Vignesh Rajah's trading history.
Who are Y-mAbs Therapeutics' active insiders?: Y-mAbs Therapeutics' insider roster includes Thomas Gad (Insider), Jorris Jan Wilms (Sr. VP & COO ), Bo Kruse (CFO), Vignesh Rajah (CMO), and Johan Wedell-Wedellsborg (Director). Learn More on Y-mAbs Therapeutics' active insiders.
Are insiders buying or selling shares of Y-mAbs Therapeutics?: During the last twelve months, insiders at the sold shares 9 times. They sold a total of 201,155 shares worth more than $2,570,307.80. The most recent insider tranaction occured on September, 16th when insider Thomas Gad sold 30,000 shares worth more than $389,100.00. Insiders at Y-mAbs Therapeutics own 22.5% of the company. Learn More about insider trades at Y-mAbs Therapeutics.
Information on this page was last updated on 9/16/2024.

Vignesh Rajah Insider Trading History at Y-mAbs Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/5/2024	Sell	1,711	$16.53	$28,282.83	33,889
11/15/2022	Buy	1,195	$4.92	$5,879.40	4,266
8/12/2021	Buy	1,374	$29.95	$41,151.30
12/2/2020	Buy	233	$51.03	$11,889.99
11/17/2020	Buy	1,464	$45.74	$66,963.36

Vignesh Rajah Buying and Selling Activity at Y-mAbs Therapeutics

Y-mAbs Therapeutics Company Overview

Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow. The company is also developing DANYELZA for the treatment of patients with second-line relapsed osteosarcoma and is in Phase II clinical study; GD2-SADA, which is in Phase I clinical trial for the treatment of GD2 positive solid tumor; and Omburtamab, a murine monoclonal antibody for the treatment of central nervous system/leptomeningeal metastases from neuroblastoma, as well as SADA PRIT technology platform. In addition, it is engages in the developing of CD38-SADA and GD2-GD3 Vaccine. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York.

Today's Range

Now: $8.28

$8.00

$8.50

50 Day Range

MA: $12.36

$8.28

$15.69

2 Week Range

Now: $8.28

$6.10

$20.90

Volume

1,143,018 shs

Average Volume

328,133 shs

Market Capitalization

$370.85 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.61

Media Humiliated: Demo of Elon’s Tech Proves They’re Wrong

From Brownstone Research | Ad

Elon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is not buying it.

Click here to watch this demo and decide for yourself.

Vignesh Rajah Biography and Net Worth

What is Vignesh Rajah's net worth?

How old is Vignesh Rajah?

What is Vignesh Rajah's salary?

How do I contact Vignesh Rajah?

Has Vignesh Rajah been buying or selling shares of Y-mAbs Therapeutics?

Who are Y-mAbs Therapeutics' active insiders?

Are insiders buying or selling shares of Y-mAbs Therapeutics?